Company intelligence / Profile preview
Arthrosi Therapeutics
San Diego, California, United Statesarthrosi.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Arthrosi's lead compound AR882 has completed enrollment in its pivotal Phase 3 REDUCE 2 trial for gout treatment. The drug has shown encouraging efficacy and safety in Phase 2 studies, including impressive results in achieving complete resolution of tophi. The company has received FDA Fast Track Designation for AR882 in tophaceous gout. The REDUCE 2 trial is expected to be completed in the first half of 2026, and a replicate Phase 3 study (REDUCE 1) was initiated in Q1 2025.
- Therapeutic areas
- NephrologyRheumatology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Arthrosi Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Arthrosi Therapeutics.